<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734445</url>
  </required_header>
  <id_info>
    <org_study_id>2018/11</org_study_id>
    <nct_id>NCT03734445</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin C, D and Zinc Supplementation on the Immune and Inflammatory Process in Type 2 Diabetic Subjects</brief_title>
  <official_title>Effect of Vitamin C, Vitamin D and Zinc Supplementation on the Immune and Inflammatory Process in Type 2 Diabetic Subjects in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma del Estado de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma del Estado de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 Diabetes Mellitus According to the World Health Organization (WHO), there are more
      than 346 million individuals with diabetes, of which 90% are type 2. Global estimations for
      the year 2030 predict an epidemic increase that will reach 366 million. According to the
      National Nutrition and Health Survey of 2006 (ENSANUT2005), there are 6.4 million type 2
      diabetic subjects in Mexico.

      According to the calculation of the sample size, the investigators will include 120 adults
      with type 2 diabetes mellitus selected from the outpatient preventive medicine offices of
      health centres in the State of Mexico who will divided in two groups: supplement and placebo
      (60 per group). After having been invited to participate and obtaining the informed consent,
      study subjects will be evaluated for dietary information, as well as biochemical biomarkers
      of metabolic control, anthropometric, immune and inflammatory markers, gut microbiota and
      oxidative stress, before beginning the trial, and after 12 and 24 weeks of supplementation.
      They will have a monthly follow-up visit for evaluation of adherence and adverse effects, as
      well as delivery of the supplement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomly allocated to a supplementation with 1000 mg vitamin C, 400 IU
      vitamin D and 10 mg of zinc or placebo group, during 24 weeks. Subjects and researchers will
      be blinded to the supplement or placebo in order to guarantee double-blinding.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 9, 2020</start_date>
  <completion_date type="Anticipated">March 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly allocated to two groups (vitamin supplement or placebo), with a duration of 24 weeks. Dietary and compliance monthly follow-up and baseline, 12 and 24-week measurements.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Vitamin Supplement and placebo will be packaged by others not including the investigators, code will be kept secret until the end of the trial or unless a secondary effect is registered and merits the opening of the code</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycemia from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Measured in plasma with a Selectra II automated equipment with Randox reactants, in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycosilated Hemoglobin (Hb1Ac) from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Measured in plasma with a Selectra II automated equipment with Randox reactants, in percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma insulin from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in uU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Homeostatic Model Assesment for Insulin Resistance (HOMA-IR) from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Calculated from: HOMA-IR = (insulin x glucose)/405</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma cytokines from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Tumor Necrosis Factor alfa (TNFα), Interferon gamma (IFN-γ), Interleukins 1 beta, 4, 6 and 10 (IL-1β, IL4, IL-6, IL10) &amp; transforming growth factor beta (TGF-β), measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma adipokines from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Adiponectin, resistin and leptin, measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in additional plasma inflammatory markers from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Apolipoproteins A and B, C-reactive protein, vascular cell adhesion protein (V-CAM), intercellular adhesion molecule (I-CAM), complement proteins C-3 and C-4, measured with Multiplex Technology in a Milliplex Luminex Equipment with Merck-Millipore reactants, in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Total cholesterol, HDL-, LDL-, Very Low Density Lipoprotein (VLDL)-cholesterol and triacylglycerides, measured in plasma with a Selectra II automated equipment with Randox reactants, in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers of oxidative stress from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Malondialdehyde (QuantiChromTM), Thiobarbituric acid reactive substances (TBARS Assay Kit), carbonylated proteins (colorimetric), antioxidant capacity (QuantiChromTM Antioxidant Assay Kit), catalase (EnzyChromTM Catalase Assay Kit), superoxide dismutase (EnzyChromTM Superoxide Dismutase Assay Kit) and glutathion peroxidase (metaphosphoric acid SIGMA ALDRICH y EnzyChromTM GSH/GSSG Assay Kit, measured with various commercial kits, in U/μL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte subpopulations from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Cluster of desgination 4, 8, 17 and 19 (CD4+, CD8+, CD17+ and CD19+), measured by flow cytometry (Becton Dickinson Facs AriaMR de 6 canales), in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Intestinal microbiota patterns from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Analyzed with a Illumina sequencing equipment and Mothur y Stamp softwares, in percentage</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma vitamin C from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Measured with a Colorimetric assay, in mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in plasma vitamin D from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Measured with a commercial ELISA kit, ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in plasma zinc from baseline to 12 and 24 weeks</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Measured with a Colorimetric assay, in mg/dL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Vitamin supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effervescent tablets containing Vitamin C, Vitamin D and zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Effervescent tablets not containing Vitamin C, Vitamin D and zinc</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin Supplement</intervention_name>
    <description>Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding</description>
    <arm_group_label>Vitamin supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 25 and 55 years of age, as this is the age in which type 2 diabetes mellitus
             is more prevalent and there is less probability of encountering multiple diseases in
             the same subjects

          -  Both sexes

          -  Outpatients

          -  BMI ≥ 25

        Exclusion Criteria:

          -  Without any other chronic disease (cancer, cardiovascular diseases, arthritis and
             Alzheimer's).

          -  Severe renal insufficiency.

          -  Nephrolithiasis or history of nephrolithiasis.

          -  Hyperoxaluria.

          -  Hemochromatosis.

          -  Hypercalcaemia.

          -  Hypervitaminosis D.

          -  Using insulin.

          -  Be taking drugs such as desferrioxamine, iron, cyclosporine, indinavir (protease
             inhibitors), warfarin, thiazide diuretic, orlistat, ion exchange resins (e.g
             cholestyramine, laxatives (e.g. mineral oil, senna), vitamin d analogues (e.g.
             ergocalciferol, calcitriol, and topical calcipotriene), tetracycline antibiotics,
             quinolone antibiotics, penicillamine, biphosphonates, levothyroxine, eltrombopag.

          -  Patients with hypersensitivity to any of the active substance(s) or to any of the
             excipients.

          -  Hypersensitivity to the by-products including honey, conifers, poplars, Peru balsam,
             and salicylate.

          -  Intake of probiotics or supplemental vitamin or mineral (vitamin D, C, zinc or
             calcium) for 4 weeks before the beginning of the study.

          -  Smoking and alcohol consumption (&gt; 40 gr/ day for men and 25 gr/ day for women.

          -  Pregnant or lactating.

          -  Whose parents or grandparents are/were immigrant or of native origin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma del Estado de Mexico</investigator_affiliation>
    <investigator_full_name>Roxana Valdés Ramos</investigator_full_name>
    <investigator_title>DSc, Head of Nutrition and Health Group, Full-time professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus type 2</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Cinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Baothman+OA%2C+Zamzami+MA%2C+Taher+I%2C+ABugaker+J%2C+Abu-Farhca+MA.+The+role+of+Gut+Microbiota+in+the+development+of+obesity+and+diabetes</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Barengolts+E.+Vitamin+D+and+prebiotics+may+benefit+the+intestinal+microbacteria+and+improve+glucose+homeostasis+in+prediabetes+and+type+2+diabetes.</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Capdor+J%2C+Foster+M%2C+Petocz+P%2C+Samman+S.+Zinc+and+glycemic+control%3A+a+meta-analysis+of+randomised+placebo+controlled+supplementation+trials+in+humans.</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Fruit+and+vegetable+intake+and+the+association+with+glucose+parameters%3A+a+cross-sectional+analysis+of+the+Let%27s+Prevent+Diabetes+Study</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/15008827</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Foster+M%2C+Petocz+P%2C+Samman+S.+Inflammation+markers+predict+zinc+transporter+gene+expression+in+women+with+type+2+diabetes+mellitus</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Gokhale+NH%2C+Acharya+AB%2C+Patil+VS%2C+Trivedi+DJ%2C+Thakur+SL.+(2013)+A+short-term+evaluation+of+the+relationship+between+plasma+ascorbic+acid+levels+and+periodontal+disease+in+systemically+healthy+and+type+2+diabetes+mellitus+subjects</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Jansen+J%2C+Rosenkranz+E%2C+Overbeck+S%2C+Warmuth+S%2C+Mocchegiani+E%2C+Giacconi+R%2C+Weiskirchen+R%2C+Karges+W%2C+Rink+L.+Disturbed+zinc+homeostasis+in+diabetic+patients+by+in+vitro+and+in+vivo+analysis+of+insulinomimetic+activity+of+zinc</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/20606205</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/22699609</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Kayaniyil+S%2C+Vieth+R%2C+Retnakaran+R%2C+Knight+JA%2C+Qi+Y%2C+Gerstein+HC%2C+et+al.+Association+of+vitamin+D+with+insulin+resistance+and+beta-cell+dysfunction+in+subjects+at+risk+for+type+2+diabetes.+Diabetes+care</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Ley%2C+R.+E.%2C+Lozupone%2C+C.+A.%2C+Hamady%2C+M.%2C+Knight%2C+R.+%26+Gordon%2C+J.+I.+Worlds+within+worlds%3A+evolution+of+the+vertebrate+gut+microbiota</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Mandl+J%2C+Szarka+A%2C+Bángheyl.+(2009)+Vitamin+C%3A+update+on+physiology+and+pharmacology.+B+J+Pharmacol</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Efficacy+of+supplementary+vitamins+C+and+E+on+anxiety%2C+depression+and+stress+in+type+2+diabetic+patients%3A+a+randomized%2C+single-blind%2C+placebo-controlled+trial</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Effect+of+vitamin+C+supplementation+on+postprandial+oxidative+stress+and+lipid+profile+in+type+2+diabetic+patients.</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/9794114</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Rafighi%2C+Z.%2C+Shiva+A.%2C+Arab%2C+S.+and+Mohd+Yousof%2C+R.+(2013)+Association+of+dietary+vitamin+C+and+E+intake+and+antioxidant+enzymes+in+type+2+diabetes+mellitus+patients</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Zinc+as+a+potential+coadjuvant+in+therapy+for+type+2+diabetes.</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Sarmento+RA%2C+Silva+FM%2C+Sbruzzi+G%2C+Schaan+BD%2C+Almeida+JC.+Antioxidant+micronutrients+and+cardiovascular+risk+in+patients+with+diabetes%3A+a+systematic+review</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/25284151</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/27915988</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Insulino-mimetic+and+anti-diabetic+effects+of+zinc</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/28615382</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/12502486</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/22375253</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>scientific article</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Iman+M+Ibrahim%2C+and+Manal+M+Alkady.+Role+of+Vitamin+D+on+glycemic+control+and+oxidative+stress+in+type+2+diabetes+mellitus</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03734445/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03734445/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

